



AML3D®

AML3D Limited

35 Woomera Avenue  
Edinburgh SA 5111  
AUSTRALIA

info@aml3d.com  
+61 8 8258 2658  
www.aml3d.com

## DECEMBER 2025 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX: AL3) ("AML3D" or "the Company"), a leader in large scale Wire Additive Manufacturing ("WAM") technology and 3D metal printing solutions, is pleased to provide the Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2025 (2Q26).

### KEY HIGHLIGHTS DURING THE QUARTER

Customer receipts in 2Q26 were **A\$2.3 million**, an increase of 360% on the prior comparable period (PCP). This significant growth in customer receipts reflects the continued success of the US Scale up strategy, the key contributor to the A\$9 million of orders in hand<sup>1</sup> as AML3D entered FY26. An additional A\$7.5 million of orders have already been signed in FY26, to give a **current total of A\$16.5 million in orders** to be delivered in the current financial year.

The key highlights from the quarter under review include:

- \$1.7 million ARCEMY® order from FasTech<sup>2</sup>, a US defence and industry metal printing supplier
- \$4.5 million order for 2 custom ARCEMY® systems for Newport News Shipbuilding ('NNS'), a division of HII<sup>3</sup>
- Design of an innovative, rapid deployment ARCEMY® small system in response to a \$1.2 million Austal order<sup>4</sup>.

AML3D's huge growth opportunity within the US Navy Maritime Industrial Base (MIB) was underpinned by the US Department of the Navy issuing a Letter of Intent (LOI) during 1Q26. The LOI identifies AML3D's proprietary ARCEMY® technology as key to meeting an estimated, **A\$150 - \$200 million** MIB additive manufacturing opportunity<sup>5</sup>. The initial **A\$4.5 million** order from Huntington Ingalls Industries (HII), the largest military shipbuilder in the USA, demonstrates progress on converting the LOI into confirmed sales

### GROWTH STRATEGY

#### US scale up

AML3D launched the US Scale up strategy, in 2023, in response to strong demand signals for AML3D's proprietary, advanced additive manufacturing technology from the US defence sector, notable US Navy Maritime Industrial Base (MIB). Current FY26 **orders of A\$16.5 million** demonstrate AML3D's continuing success in converting this strong demand to confirmed sales. The scale of the opportunity for AML3D to continue to accelerate US growth was put into context by the US Department of the Navy Letter of Intent (LOI), issued during 1Q26, which identified an estimated, **A\$150 - \$200 million** MIB additive manufacturing requirement between 2026 and 2030. The LOI identifies AML3D's proprietary ARCEMY® technology as key to meeting this requirement.

In addition to the A\$9 million of orders carried into FY26, AML3D signed a A\$1.2m portable, rapid deployment ARCEMY® Small system during Q126 with Austal USA for deployment at the U.S. Navy's Additive Manufacturing

<sup>1</sup> AML3D Ltd, [2025 Annual Report to shareholders](#), 18 August 2025

<sup>2</sup> AML3D Ltd, [\\$1.7M Arcemy Order from US Defence and Industry Supplier](#), 18 November 2025

<sup>3</sup> AML3D Ltd, [~\\$4.5 million ARCEMY® order from the largest shipbuilder in the USA](#), 20 October 2025

<sup>4</sup> AML3D Ltd, [AML3D Receives \\$1.2M Portable Arcemy System Order](#), 21 July 2025

<sup>5</sup> AML3D Ltd, [US Navy Issues AML3D with Letter of Intent and Forecast](#), 7 July 2025



Centre of Excellence in Danville, Virginia. This has been followed, in 2Q26, by an initial **A\$4.5 million ARCEMY order** from HII in support of the US Navy's MIB. The HII order is for 2 custom ARCEMY X systems for HII's Newport News Shipbuilding ("NNS") division. AML3D is targeting additional near-term sales to HII.

The high demand across the US MIB also resulted in the ~\$1.7 million ARCEMY® order from US defence and industry metal printing supplier FasTech. This order expands US 3D metal printing supplier FasTech's capabilities and AML3D's US profile. FasTech provides additive manufacturing services to the US Defence, Aerospace, Energy and other high-demand industrial sectors. The FasTech order will allow AML3D to leverage ARCEMY®'s success in the US Defence sector to access new industrial manufacturing markets, a key objective of the US scale up strategy.

While meeting the huge demand forecast by the US Department of the Navy is AML3D's most significant growth opportunity, the company is continuing to develop opportunities in non-defence, industrial manufacturing. AML3D successfully entered the US Utilities sector with the completion of a A\$2.27million order for an ARCEMY® X for the Tennessee Valley Authority (TVA)<sup>6</sup> in August 2025. The TVA is federally owned and is the sixth-largest power supplier and largest public utility in the USA. AML3D's Technology Centre at Stow, Ohio is continuing to produce material qualification prints for non-defence industry players in the US.

## UK & Europe

AML3D has identified the initial demand signals that informed the US Scale Up strategy are now present in the UK and emerging in other key European defence markets. AML3D has already signed a A\$1.2 million material feasibility and test block program with BAE Systems UK<sup>7</sup> and has plans and funding to establish a European facility to meet the expected strong growth in the region. In addition, AML3D worked on a confidential component manufacturing order for a UK defence prime supplier. Entry into the U.K. Defence market is a key part of the next phase of AML3D's growth strategy.

During the previous quarter AML3D put in place 2 distribution agreements to support the strong, emerging demand signals across the UK and Europe. A two year, non-exclusive, distribution partnership with, Scotland based, Arc Additive Limited<sup>8</sup> covers the UK and Europe, while a similar deal with, German based, DMFG Solutions GmbH<sup>9</sup> will focus on European markets. Funding for the \$5 million European Technology Hub has been agreed and will be optimised to meet the growing European demand trends as they crystallise.

## Australia

AML3D's Australian facilities are providing additional capacity to support the roll out of the US Scale Up strategy and UK Defence contracts. AML3D has been classified by Austrade as one of the largest exporters under AUKUS<sup>10</sup>. The Minister for Defence Industry of Australia, Pat Conroy, has asked to be kept informed of the evolution of AML3D's operating model for US MIB. Minister Conroy is interested in identifying opportunities to incorporate US MIB best practice when integrating additive manufacturing into Australia's AUKUS supply model.

The Company's ARCEMY technology has already supported the Australian Government's Defence Science and Technology Group's marine<sup>11</sup> and aerospace<sup>12</sup> programs and to manufacture a prototype for BAE Systems Maritime Australia's Hunter Class Frigate Program<sup>13</sup>.

<sup>6</sup>AML3D Ltd, [ARCEMY X Operational at the Largest Public Utility in USA](#), 4 August 2025

<sup>7</sup>AML3D Ltd, [AML3D expands into UK Defence market with alloy test contract](#), 15 April 2025

<sup>8</sup> AML3D Ltd, [AML3D Accelerates Entry into Europe with UK Distributor Deal](#), 28 July 2025

<sup>9</sup> AML3D Ltd, [AML3D Extends European Distribution Capabilities](#), 6 August 2025

<sup>10</sup> AML3D Ltd, [AML3D Supports AUKUS Supply Chain](#), 6 January 2025

<sup>11</sup> AML3D Ltd, [AML3D Signed Marine Test Parts Contract with DST](#), 23 April 2024

<sup>12</sup> AML3D Ltd, [Aerospace Contract Expands Presence in AU Defence](#), 1 May 2024

<sup>13</sup> AML3D Ltd, [AML3D to Manufacture Prototype for BAE's Frigate Program](#), 1 December 2023

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.



Australia is also AML3D's Research and Development base. Ensuring AML3D's ARCEMY® systems remain at the leading edge of large scale, metal additive manufacturing technology is critical to continuing to secure ARCEMY® system sales and contract manufacturing orders over the medium to longer term. In 2Q26, AML3D, invested a further A\$0.4 million in the Advanced/Increased Deposition Rate (ADIR) project to increase ARCEMY® deposition rates and accelerate component production. AML3D's investment in ADIR being matched by a South Australian Government grant. The total budget for the ADIR project is A\$2.24 million<sup>14</sup>.

### Advocacy program

AML3D's ongoing US advocacy program to deepen relationships with key opinion leaders (KOL) and partners in the US Defence, Government and Manufacturing sectors continues and is expected to support additional MIB orders. The US advocacy program remains critical to raising the profile of ARCEMY® as a proven and leading-edge technology to revitalise the US Navy's shipbuilding and repair capabilities. Awareness amongst KOLs and partners in the US Defence, Government and Manufacturing sectors made a significant contribution to AML3D's receiving the US Department of the Navy LOI identifying A\$150 - \$200 million MIB opportunity.

The US Navy MIB includes surface ships, aircraft carriers, and munitions. The US Navy LOI maps a 5-year program to build ARCEMY® centric additive manufacturing capacity and support for the MIB. The 5-year program includes production of the initial 30 - 60 components out of the four hundred highlighted in the LOI for 2026 and rising to 1,600 components by 2030. Engagement with The MIB leadership through AML3D's advocacy program has also identified an immediate need for up to 10 ARCEMY® systems under a flexible operating model that includes options to embed the systems in the MIB supply chain and for AML3D to operate them under a contract manufacturing model.

The insights and intelligence gained through AML3D's US advocacy program will inform and optimize AML3D's plans to expand its US operations and capacity to meet the significant demand from within the MIB and US Defense Primes, including HII.

### FINANCIAL UPDATE

AML3D is announcing cash receipts of A\$2.25 million in the December 2025 quarter and increase of A\$1.76 million on the PCP.

The investment in AML3D's ARCEMY® Increase Deposition Rates (ADIR) R&D project in the December 2025 quarter was A\$0.39 million out of a total budget of A\$2.24 million.

The company's cash position remains extremely strong at A\$29.2m on 31 December 2025, which equates to more than 20 quarters of available cash.

AML3D retains the balance sheet strength to fund the company's planned investment of A\$12 million plan to more than double US manufacturing and A\$5 million plan to establish a European manufacturing and technology centre.

In the quarter under review circa A\$0.5 million of capital was invested in expanding AML3D's US facilities at Stow, Ohio.

### OUTLOOK

AML3D already has a \$16.5 million of orders in hand for the 2026 financial year.

The Company is extremely confident the 'US Scale Up' strategy, flexible operating model and strong US advocacy will drive multiple additional ARCEMY® Systems orders in the US during FY26. The US Navy LOI has already identified the

<sup>14</sup> AML3D Ltd, [AML3D Wins SA Government Grant \\$2.24M Technology Investment](#), 4 June 2024



need to install up to 100 new systems over time to drive an acceleration of MIB manufacturing and identified AML3D's ARCEMY technology as playing pivotal role.

In addition to the US defence opportunity AML3D expects its entry into the UK defence market, at the emergence of strong demand across the UK and European defence sectors, will support mid-term growth. As will AML3D's expansion into the US energy and utilities markets through the TVA ARCEMY® system sale<sup>15</sup>. Expansion into additional sectors such as, Utilities, Aerospace, Nuclear, Oil & Gas and Marine sectors will be a key driver of AML3D's strategy to create additional, medium term, growth opportunities.

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

**Sean Ebert**

Chief Executive Officer  
AML3D Limited  
T: +61 429 550 593  
E: [investor@aml3d.com](mailto:investor@aml3d.com)

**Hamish McEwin**

Chief Financial Officer  
AML3D Limited  
T: +61 429 550 593  
E: [investor@aml3d.com](mailto:investor@aml3d.com)

**About AML3D Limited**

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company's patented Wire Additive Manufacturing (WAM®) process. WAM® combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY® industrial metal 3D printing systems. ARCEMY® uses WAM® to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY® is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.

<sup>15</sup>AML3D Ltd, [AML3D wins \\$2.27M ARCEMY X Contract in US Utilities Sector](#), 09 December 2024

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity			
AML3D Limited			
ABN		Quarter ended (“current quarter”)	
55 602 857 983		31 December 2025	
Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
<b>1. Cash flows from operating activities</b>			
1.1	Receipts from customers	2,245	4,740
1.2	Payments for		
	(a) research and development	(387)	(743)
	(b) product manufacturing and operating costs	(579)	(1,340)
	(c) advertising and marketing	(92)	(149)
	(d) leased assets	-	-
	(e) staff costs	(1,764)	(3,552)
	(f) administration and corporate costs	(1,047)	(1,874)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	60	377
1.5	Interest and other costs of finance paid	(40)	(81)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	197	629
1.8	Other (provide details if material)	-	-
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(1,407)</b>	<b>(1,993)</b>
<b>2. Cash flows from investing activities</b>			
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(486)	(589)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
2.2	Proceeds from disposal of:		
(a)	entities	-	-
(b)	businesses	-	-
(c)	property, plant and equipment	-	5
(d)	investments	-	-
(e)	intellectual property	-	-
(f)	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(486)</b>	<b>(584)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	400	1,479
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(56)	(109)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>344</b>	<b>1,370</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	30,721	30,398
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,407)	(1,993)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(486)	(584)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	344	1,370
4.5	Effect of movement in exchange rates on cash held	(6)	(25)
4.6	<b>Cash and cash equivalents at end of period</b>	<b>29,166</b>	<b>29,166</b>
<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	6,126	6,721
5.2	Call deposits	23,040	24,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>29,166</b>	<b>30,721</b>
<b>6. Payments to related parties of the entity and their associates</b>		<b>Current quarter \$A'000</b>	
6.1	Aggregate amount of payments to related parties and their associates included in item 1		-
6.2	Aggregate amount of payments to related parties and their associates included in item 2		-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>			

<p><b>7. Financing facilities</b>  <i>Note: the term 'facility' includes all forms of financing arrangements available to the entity.</i>  <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i></p> <p>7.1 Loan facilities</p> <p>7.2 Credit standby arrangements</p> <p>7.3 Other (please specify)</p> <p><b>7.4 Total financing facilities</b></p> <p><b>7.5 Unused financing facilities available at quarter end</b></p> <p>7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p> <p>N/A</p>	<p><b>Total facility amount at quarter end</b>  <b>\$A'000</b></p> <p>-</p> <p>-</p> <p>-</p> <p>-</p> <p><b>Unused financing facilities available at quarter end</b></p> <p>-</p>	<p><b>Amount drawn at quarter end</b>  <b>\$A'000</b></p> <p>-</p> <p>-</p> <p>-</p> <p>-</p>
<p><b>8. Estimated cash available for future operating activities</b></p>		
<p><b>\$A'000</b></p>		
<p>8.1 Net cash from / (used in) operating activities (item 1.9)</p> <p>8.2 Cash and cash equivalents at quarter end (item 4.6)</p> <p>8.3 Unused finance facilities available at quarter end (item 7.5)</p> <p>8.4 Total available funding (item 8.2 + item 8.3)</p>	<p>(1,407)</p> <p>29,166</p> <p>-</p> <p>29,166</p>	
<p><b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b></p>		
<p>21</p>		
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>		
<p>8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:</p>		
<p>8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?</p>		
<p>Answer: N/A</p>		
<p>8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?</p>		
<p>Answer: N/A</p>		
<p>8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?</p>		
<p>Answer: N/A</p>		
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 January 2026

Authorised by: the Board  
(Name of body or officer authorising release – see note 4)

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.